FindMyKOL
Clinical trialNCT00164736CompletedPhase 3Interventional

Breastfeeding, Antiretroviral, and Nutrition Study

NCT00164736 is a phase 3 interventional trial sponsored by Centers for Disease Control and Prevention. As of 21 Nov 2026, it is completed. It studies Infant nevirapine and Maternal zidovudine/lamivudine/lopinavir-ritonavir in HIV Infections. The registry lists an enrollment of 2,369 participants at 1 site in 1 country. The registry lists a start date of 31 Mar 2004 and a primary completion date of 31 Jan 2010. One of its registered investigators has a FindMyKOL profile.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00164736
FieldValue
Registry IDNCT00164736
StatusCompleted
PhasePhase 3
Study typeInterventional trial
Lead sponsorCenters for Disease Control and Prevention
Enrollment2,369
Registered sites1
Countries1
ConditionsHIV Infections
DrugsInfant nevirapine and Maternal zidovudine/lamivudine/lopinavir-ritonavir
Start31 Mar 2004
Primary completion31 Jan 2010
Study completion31 Jan 2010
Last update posted23 Apr 2010

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a comparative clinical trial among HIV-infected women and their infants to determine: 1. the benefit of nutritional supplementation given to women during breastfeeding 2. the benefit and safety of antiretroviral (ARV) medications given either to infants or to their mothers to prevent HIV transmission during breastfeeding 3. the feasibility of exclusive breastfeeding followed by early, rapid breastfeeding cessation

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Malawi1 site
  • Kamuzu Central Hospital, Bottom Hospital

    Lilongwe

Sites by country

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Infant nevirapineMaternal zidovudine/lamivudine/lopinavir-ritonavir
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00164736

Each answer restates registry values shown on this page.

What is NCT00164736?

NCT00164736 is a phase 3 interventional trial sponsored by Centers for Disease Control and Prevention. It studies Infant nevirapine and Maternal zidovudine/lamivudine/lopinavir-ritonavir in HIV Infections.

Who leads NCT00164736?

The registry names Charles van der Horst, MD (study chair, University of North Carolina, Chapel Hill), Denise J Jamieson, MD, MPH (principal investigator, CDC, Atlanta, GA) and Peter Kazembe, MB ChB (principal investigator, Kamuzu Central Hospital) as overall officials.

Where does NCT00164736 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: Malawi.

Which drugs does NCT00164736 study?

The registered drug and biological interventions are Infant nevirapine and Maternal zidovudine/lamivudine/lopinavir-ritonavir.

When did NCT00164736 end?

The registry lists a primary completion date of 31 Jan 2010 and a study completion date of 31 Jan 2010. The sponsor last updated the record on 23 Apr 2010.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.